What did the FDA decide on tanning beds?

FDA withdraws proposed ban on minors using tanning beds

The FDA has withdrawn a proposed rule that would have barred Americans under 18 from using tanning beds. The action reverses a long-running federal effort to tighten regulation of indoor tanning—an issue tied to skin cancer risk and the broader question of how strongly regulators should limit exposure among younger people.

The proposed rule had been in the works for more than a decade, reflecting continued concern from medical groups and public health advocates about the dangers of ultraviolet (UV) tanning. In the latest developments, the FDA backed away from the restriction, which has also been associated in reporting with political support from Robert F. Kennedy Jr.

What changes for consumers

With the proposed ban withdrawn, the federal action that would have restricted minors’ access does not move forward as proposed. That means states and other existing rules may still govern tanning bed access, but a uniform nationwide FDA prohibition for under-18s is no longer part of the regulatory pipeline described by the earlier proposal.

Why it matters

Indoor tanning is a modifiable exposure linked to increased risk of skin cancers. When regulators consider age limits, the policy aim is typically to reduce the likelihood that adolescents and young adults accumulate harmful UV exposure during periods when cancer risk can be amplified by behavior and biology.

The withdrawal also underscores how health policy can be influenced by court challenges, political dynamics, and shifting enforcement priorities. For public health messaging, it means clinicians and prevention advocates may need to continue emphasizing UV safety and alternative options rather than relying on a new federal age restriction.